about
Fibroblast growth factor 23, iron and inflammation - are they related in early stages of chronic kidney disease?Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized studyDevelopment of asthmatic response upon bronchial allergen challenge is associated with dynamic changes of interleukin-10-producing and interleukin-10-responding CD4+ T cells.Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety.Endothelial progenitor cell levels in juvenile idiopathic arthritis patients: effects of anti-inflammatory therapies.Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations.The plasmin system in airway remodeling.Decreased CD127 expression on CD4+ T-cells and elevated frequencies of CD4+CD25+CD127- T-cells in children with long-lasting type 1 diabetes.Omalizumab treatment in brittle asthma.Pharmacological consequences of inhaled drug delivery to small airways in the treatment of asthma.The statement of the Polish Society of Allergology experts on the treatment of difficult-to-treat asthma.The statement of the Polish Society of Allergology regarding necessary changes in therapeutic program of severe IgE-mediated allergic asthma with omalizumab.Reduced clot retraction rate and altered platelet energy production in patients with asthma.Enhanced pretreatment CD25 expression on peripheral blood CD4+ T cell predicts shortened survival in acute myeloid leukemia patients receiving induction chemotherapy.Circulating classical CD14++CD16- monocytes predict shorter time to initial treatment in chronic lymphocytic leukemia patients: Differential effects of immune chemotherapy on monocyte-related membrane and soluble forms of CD163.Vitamin D3 Treatment Decreases Frequencies of CD16-Positive and TNF-α-Secreting Monocytes in Asthmatic Patients.Changes in blood eosinophilia during omalizumab therapy as a predictor of asthma exacerbationPredictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase.The role of endothelium-derived mediators in exercise-induced bronchoconstriction.Changes in high-sensitivity C-reactive protein in serum and exhaled breath condensate after intensive exercise in patients with allergic asthma.RANTES in exhaled breath condensate of allergic asthma patients with exercise-induced bronchoconstriction.Lower proportions of CD4+CD25(high) and CD4+FoxP3, but not CD4+CD25+CD127(low) FoxP3+ T cell levels in children with autoimmune thyroid diseases.Relationship between circulating endothelial progenitor cells and endothelial dysfunction in children with type 1 diabetes: a novel paradigm of early atherosclerosis in high-risk young patients.Phenotypic correlations between monocytes and CD4+ T cells in allergic patients.The influence of inhaled corticosteroids on exhaled nitric oxide in stable chronic obstructive pulmonary disease.The concentration of kynurenine in rat model of asthma.Plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in sputum of allergic asthma patients.Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators.Effect of ciclesonide and fluticasone on exhaled nitric oxide in patients with mild allergic asthma.Zonulin, inflammation and iron status in patients with early stages of chronic kidney disease.Asthma is associated with reduced fibrinolytic activity, abnormal clot architecture, and decreased clot retraction rate.Comment on "Calcium preparations do not inhibit allergic reactions: a randomized controlled trial".High-dose bee venom exposure induces similar tolerogenic B-cell responses in allergic patients and healthy beekeepers.Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom HypersensitiIron Status and Inflammation in Early Stages of Chronic Kidney Disease.An assessment of an amidolytic assay for factor VII in the laboratory control of oral anticoagulants.Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertensionEffects of 1 gram oral or intravenous aspirin on urinary excretion of thromboxane B2 and 6-keto-PGF1α in healthy subjectsPlasminogen Activator Inhibitor-1 Plasma Concentration in Allergic Asthma Patients during Allergen ChallengeThe -675 4G/5G plasminogen activator inhibitor-1 promoter polymorphism in house dust mite-sensitive allergic asthma patients
P50
Q33904467-26234BE5-422A-46A2-B945-D7FF97993432Q33909318-49F7F9DD-6102-47E5-8486-C237A49FB407Q34474656-CDB8C70F-8559-411D-B01C-BF64D542F6DBQ34644636-21E2D000-F78F-4E58-8100-8FF628B4F9F8Q35108691-58D6D0E9-6EE2-4E8C-B258-9FA99F21ABA6Q35556002-0ADCE9A2-29F1-4D86-953B-A5E15B525F69Q35687812-C17A3F0E-B444-4A61-8467-9BC7CEDFAA9AQ37375647-D8B8D8B7-D01F-47F1-89AE-E6745BE89408Q37634330-0429E8C1-0EDA-4995-9A85-978700CAD658Q38239365-722452C0-BB0D-4EFF-81D3-800FC4EA0ECDQ38545800-8CAF2ACD-61B4-4EDE-B4FC-C8451BB84840Q38545802-94615C28-C930-4056-9F65-DC5A0F49FA65Q39795377-C20EA5DB-CC44-4523-8733-68888BFBA754Q40154314-1C04D2E7-688E-41B4-9543-06D4A60F7DF0Q40775213-70C8E4C3-71C9-41A6-B400-6BC2A7D02F2EQ41075618-ABE79157-AA1D-48C9-B804-BA9C732F72FAQ41880272-B1F1E153-93DF-4301-AF12-845FA3B3264EQ41987845-A66E9E8E-C74F-48F5-BDB0-FA9933859B09Q42170853-DC9F58F0-976F-44E2-876C-9BBC778F1D3AQ43112815-A0CD6881-60FF-4C19-9110-499F0D3E1D39Q43227195-1E254812-76F7-4F40-9F4E-AC81B301EA66Q43540286-ABF72F2F-75B8-45B3-942D-EED1BF101CFBQ43866753-04D92157-91B0-4BC6-B144-8C4DD32688E2Q45830978-E210B7F4-E47B-40ED-8142-33893B40189BQ46530790-D2171942-FBD1-431A-A1A1-C3C71DE2EB9EQ46562910-72850CB8-2189-4253-8E4D-71905E2862C6Q46562918-AD8479C7-57C3-49BD-B5BE-CDF49F0F954BQ46829585-11688539-B5D9-4455-8E59-D99F446317F1Q46916718-39B8C2E3-5E71-4B04-947C-89C3C9281DFDQ47406039-9A2A00F0-D67F-49D8-8C21-B75668C59785Q48678570-A8924B1E-F8A9-4BFE-8D72-6366B015B748Q49564356-8C6FA4E9-7B95-42DD-9510-B0C1B7B21F61Q50640162-758297B4-9C48-438E-ACE9-50EFAE2E189DQ52699890-057201B3-9C98-4E53-8BB2-362FB2A4C251Q53433091-945021D7-FE30-45DC-865C-2BC2BFB86800Q54042312-8722BB57-6DF0-4B5E-A7EA-4051148B4CDFQ57212429-6A50E1CB-D5AA-4D3A-AB62-82739180EF39Q58412150-3601CDCA-106C-4CFE-BE17-62DCFB06974DQ59696738-6D5A5EC7-1C95-4579-AA14-109140F87245Q59696784-E920A7AF-36BB-4795-906B-BC475119EF55
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
研究者
@zh
name
A Bodzenta-Lukaszyk
@ast
A Bodzenta-Lukaszyk
@en
A Bodzenta-Lukaszyk
@es
A Bodzenta-Lukaszyk
@nl
Anna Bodzenta-Łukaszyk
@pl
type
label
A Bodzenta-Lukaszyk
@ast
A Bodzenta-Lukaszyk
@en
A Bodzenta-Lukaszyk
@es
A Bodzenta-Lukaszyk
@nl
Anna Bodzenta-Łukaszyk
@pl
prefLabel
A Bodzenta-Lukaszyk
@ast
A Bodzenta-Lukaszyk
@en
A Bodzenta-Lukaszyk
@es
A Bodzenta-Lukaszyk
@nl
Anna Bodzenta-Łukaszyk
@pl
P31
P496
0000-0001-7187-8660